Clinical trial · Interventional
Evaluation of Transconjunctival Approach in Management of Orbital Tumors
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Many surgical approaches for excision of orbital tumors have been described. These approaches do not allow access to all orbital quadrants. Furthermore, some of these approaches are technically difficult, associated with long morbidity and post operative pain, having high rate of complications or having unacceptable cosmetic appearance. the investigators present the transconjunctival approach as an alternative procedure that allows access to orbital tumors in different locations as well as less morbidity and better cosmetic results
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Orbital Tumors | Orbital Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| transconjunctival orbitotomy approach | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- patients with orbital tumors
- description
- patients with orbital tumors will be managed by excisional or incisional biopsy via the transconjunctival orbitotomy approach
- interventionNames
- Procedure: transconjunctival orbitotomy approach
Primary outcomes (1)
- measure
- successfulness of the surgical procedure
- timeFrame
- every patient will be assessed 3 days postoperative
- description
- The procedure will be considered successful if the predetermined decision is achieved without sight threatening complications. The procedure will be considered a failure if the decision could not be achieved or if a sight threatening complication occurs.
Secondary outcomes (1)
- measure
- Early and late complications of the approach and their long term effects
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Patients with orbital tumor either benign or malignant. Exclusion Criteria: * Patients with apical tumors not accessible with transconjunctival approach. * Patients with too anterior tumors (superficial dermoid and lacrimal gland swelling). * Patients with non-neoplastic orbital lesions. * Patients with follow up period of less than 3 months
References
Publications (0)
Data not yet available